News for Exact Sciences Corporation (EXAS)

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 Ame

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due […]

Exact Sciences has helped increase colorectal cancer detection. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method.

[url="]Exact Sciences[/url] (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a [url="

PR NewswireSALT LAKE CITY, May 8, 2025 Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the CompanySALT LAKE CITY, May

Exact Sciences Corporation Q1 2025 earnings up 11%, driven by screenings & Precision Oncology. Click for more about Cologuard Plus and EXAS growth prospects.

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday. Shares of Trupanion, Inc. TRUP rose sharply during Friday's session afte...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

New York-based Classover Holdings, Inc. (KIDZ) is up over 65 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Shares of Twilio Inc. TWLO rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Twilio reported ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 mi

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in

EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now.

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional W

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other cash...

Cash flow is the money moving in and out of a business over a set period. It is important because it shows how much cash a company actually has on hand, rather than just looking at profits on paper.